Revance Therapeutics Inc (NASDAQ:RVNC) traded at $3.63 at close of the session on Friday, July 19, made a downward move of -0.41% on its previous day’s price.
Looking at the stock we see that its previous close was $3.65 . In terms of its 52-week price range, RVNC has a high of $24.87 and a low of $2.30. The company’s stock has gained about 29.82% over that past 30 days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Revance Therapeutics Inc has a market cap of $379.68 million. Estimates by analysts give the company expected earnings per share (EPS) of -$0.53, with the EPS growth for the year raised at -$2.1 for 2024 and -$0.88 for next year. These figures represent 45.20% and 58.10% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $66.06 million, with a low of $61.95 million and a high of $71.57 million. The median projection represents growth squeezing down to 13.60% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2024 is expected to hit $276.79 million, or 18.30% up from figures reported last year.
There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the RVNC stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 50% Sell. Long term indicators on average place the stock in the category of 100% Sell.
Looking further, we note the current price level is 22.40% off its SMA20 and 19.37% from its 50-day simple moving average. The RSI (14) is pointing at 60.00 while the volatility over the past week is 11.30% and jumps to 9.38% over the past one month. The beta value is 0.99, while the average true range (ATR) is currently pointing at 0.30.
Coming back to Revance Therapeutics Inc (NASDAQ:RVNC), we note that the average 3-month trading volume was 2.02 million. Current shares outstanding are 104.45 million.
The insiders hold 8.72% of the company’s shares while institutions hold 85.20%. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -58.65% down in year-to-date price movement.
